Trial Profile
Bleeding Events and Oral Anticoagulant Treatment in Non-Valvular Atrial Fibrillation (Heart-BEAT): A Cohort Study Based on CPRD-HES Data
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 16 Oct 2018
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Vitamin K antagonists (Primary)
- Indications Embolism and thrombosis
- Focus Adverse reactions
- Acronyms Heart-BEAT
- Sponsors Bristol-Myers Squibb
- 09 Oct 2018 Planned End Date changed from 31 Aug 2019 to 31 Aug 2018.
- 09 Oct 2018 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
- 09 May 2017 Planned End Date changed from 1 Aug 2018 to 31 Aug 2019.